GlaxoSmithKline PLC ADR GSK
-
Healthcare Dogs Stay Steady In April
By Fredrik Arnold : This monthly report series began applying dog dividend methodology to each of eight major market sectors in December. The sectors were, in alphabetical order: basic materials; consumer goods; financial; healthcare; industrial goods; services; technology; utilities. A ninth ...
-
Johnson & Johnson: An Uncommon Opportunity
By Rajiv Tarigopula : Johnson & Johnson ( JNJ ) , one of the world's leaders in the pharmaceutical, medical devices, and general consumer products industries, is a supreme opportunity for long-term value investors. Trading near $63 today, Johnson & Johnson has a very healthy dividend yield of over
-
NeuVax Developer Dr. Peoples Eliminates Speculation For Facts
By Brian Nichols : Cancer is the second leading cause of death in the U.S., with nearly 1.6 million new cases each year that account for over 550,000 deaths . The disease costs the U.S. healthcare system an estimated $124 billion annually with breast cancer being the highest cost accounting for ...
-
GSK to drop Human Genome bid if "poison pill" stands
LONDON (Reuters) - GlaxoSmithKline said it would not proceed with its $2.6 billion offer for Human Genome Sciences unless the U.S. biotechnology company dropped a "poison pill" shareholder rights plan imposed to block the deal.
-
GSK ( GSK ) ammends the conditions of its $2.6B tender offer for Human Genome (HGSI), requiring that the latter redeem or invalidate its poison pill.
GSK ( GSK ) ammends the conditions of its $2.6B tender offer for Human Genome ( HGSI ), requiring that the latter redeem or invalidate its poison pill. Post your comment!
-
GlaxoSmithKline: The Good News Just Keeps On Coming
By Cris Frangold : Just last month GlaxoSmithKline (NYSE: GSK ) was in the news for a move to acquire Human Genome Sciences (NASDAQ: HGSI ), its partner of up to twenty years for $2.6 …
-
Johnson & Johnson Now Poised To Hit $68 High
By Cris Frangold : Johnson & Johnson ( JNJ ) is a sound defensive investment for any conservative investors interested in the long term. Johnson & Johnson has steadily increased its stock price and earnings despite massive recalls and litigation issues. Johnson & Johnson continues to be able to ...
-
XLV Health Care Select Sector SPDR ETF Analysis, Report, Research, 5 Star Rating – Morningstar
… foreign health-care companies, the index excludes international health-care behemoths such as Novartis NVS, GlaxoSmithKline GSK , Roche, and Sanofi-Aventis. That said, we'd note that most of the firms included here are large multinational firms with …
-
A 'Least-Bad' Option For Foreign Developed Equity Exposure
… high-quality global firms such as Vodafone ( VOD ), British American Tobacco ( BTI ), HSBC ( HBC ), and GlaxoSmithKline ( GSK ). In fact, large-cap U.K. equities (in pound sterling) are actually less volatile than large-cap U.S. equities …
-
Interest Growing In Cancer Stem Cell Biotechs
By A John Hodge : In two weeks more than 25,000 cancer specialists will come together at the annual ASCO meeting in Chicago. There will be 1,000's of scientific abstracts released, and investors will pay close attention as the meeting always produces a number of market moving developments. I am ...